requires immediate discontinuation of the drug. 1 Characteristically, patients experience a Background -Pneumonitis is a rare but potentially life threatening side effect of prodromal phase with progressive cough, dyspnoea, and malaise which can last from a few methotrexate treatment for rheumatoid arthritis which needs to be distinguished days up to several weeks. At this stage incipient methotrexate pneumonitis needs to be disfrom interstitial lung disease due to rheumatoid arthritis.
Results -Methotrexate pneumonitis was
The value of bronchoalveolar lavage (BAL)
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associated with an increase in the lym-in this situation is unclear. We have therefore 
monitis.
Rheumaklinik Bad were diagnosed according to the criteria of (Thorax 1997; 52:377-379) Bramstedt, Oskar-AlexanderCarson et al, Schnabel, Richter, Bauerfeind, Gross required to make a diagnosis of methotrexate age was 62 (55-69) years, the disease duration was 78 (14-152) months, and the methotrexate pneumonitis. Three patients also had scattered ground glass opacities on high-resolution com-dose was 15 (10-25) mg/week. These patients had mild or moderate exertional dyspnoea, puted tomographic (HRCT) scanning. Patient no. 3 had a normal chest radiograph and no which was essentially stable over time, a decreased vital capacity or carbon monoxide pathological diagnosis was made but widespread ground glass opacities were seen on the transfer factor, and increased interstitial markings on the chest radiograph. None had any HRCT scan. Current doses of methotrexate were 15 mg/week in patients 1, 2, and 4 and appreciable constitutional symptoms suggestive of drug hypersensitivity. At the time of 25 mg/week in patient 3. Further characteristics are presented in table 1.
examination the four patients with methotrexate pneumonitis, seven of the eight with The first control group comprised 11 women and five men with rheumatoid arthritis who interstitial lung disease, and eight of the 16 methotrexate controls were on prednisone, the were being treated with methotrexate without clinical, radiological, or functional evidence of median daily dose being 7.5 mg in the first two groups and 5 mg in the last. interstitial lung disease (methotrexate controls). Their median age was 59 (95% conBronchoalveolar lavage was carried out in a single lung segment with 240 ml sterile 0.9% fidence interval 53-61) years, the disease duration was 90 (48-96) months, and the saline. The cell differential count was determined by microscopic examination of cytomethotrexate dose was 22.5 (15-22.5) mg/ week (table 1). The second control group in-spin preparations stained with May-GiemsaGrü nwald. For immunotyping BAL lymphocluded eight patients (four men) with rheumatoid arthritis who were being treated with cytes were labelled with fluorescent anti-CD3, anti-CD4, and anti-CD8 (Coulter, Krefeld, methotrexate and who had developed interstitial lung disease secondary to rheumatoid Germany and Becton Dickinson, Heidelberg, Germany) and counted in a Coulter EPICS arthritis (methotrexate+ILD). Their median II flow cytometer. Infection with conventional bacterial pathogens, acid-fast bacteria, Legionella species, Chlamydia species, Pneumocystis carinii, and Mycoplasma species was excluded by appropriate methods.
Results
No significant difference was found in the total number of BAL cells recovered from the patients with methotrexate pneumonitis and the two control groups (table 1). All four patients with methotrexate pneumonitis had an increase in the proportion of lymphocytes in the BAL fluid to 68%, 62%, 33%, and 40% (normal in this laboratory <15%). The eosinophil count was normal in all four patients but one patient had an increased proportion of eosinophils to 4% (normal <1%). Five of the 16 methotrexate controls had an increased proportion of lymphocytes with individual values ranging from 18% to 61%, and seven of the neutrophils (9% and 12%) in two patients.
Immunotyping of the BAL lymphocytes was tinguished from interstitial lung disease due
